glp-1 eye problems Focus on drugs & GLP-1 drugs are associated with

Learn about the expected appearance of GLP-1 injections, how to recognize quality issues, and when to consult your healthcare provider if color changes occur.

RCTs using dedicated retinal imaging are required to determine the causal relationship with these therapies

The mean weight loss among patients prescribed GLP-1 analogue monotherapy at 12 months was 11.42kg, SD 9.95 (9.6% TBWL)

Federally-registered compounding facilities stopped making tirzepatide on May 22

And other biotech news stories of the day, brought to you by The Readout.

Tirzepatide is a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly, available under two brand names: Zepbound (FDA-approved for chronic weight